Laura Ferro,Roberto Porta,Massimo Iacobelli,Alessandro Massimo Gianni,Carmelo Carlo Stella
申请号：
US14323918
公开号：
US09782429B2
申请日:
2014.07.03
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.
